Symbols / ROIV Stock $29.15 -0.48% Roivant Sciences Ltd.

Healthcare • Biotechnology • United Kingdom • NMS
ROIV (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Stock Fundamentals
Scroll to Statements
Market Cap 20.86B Enterprise Value 17.15B Income -809.24M Sales 13.31M Book/sh 6.02 Cash/sh 6.33
Dividend Yield — Payout 0.00% Employees 750 IPO — P/E — Forward P/E -25.15
PEG — P/S 1567.44 P/B 4.85 P/C — EV/EBITDA -13.56 EV/Sales 1288.25
Quick Ratio 29.81 Current Ratio 30.66 Debt/Eq 2.19 LT Debt/Eq — EPS (ttm) -1.17 EPS next Y -1.16
EPS Growth — Revenue Growth -77.80% Earnings 2026-05-28 ROA -14.47% ROE -19.14% ROIC —
Gross Margin 0.00% Oper. Margin -169.65% Profit Margin 0.00% Shs Outstand 715.70M Shs Float 531.90M Short Float 4.59%
Short Ratio 4.05 Short Interest — 52W High 30.33 52W Low 10.58 Beta 1.21 Avg Volume 6.01M
Volume 8.21M Target Price $35.67 Recom Strong_buy Prev Close $29.29 Price $29.15 Change -0.48%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$35.67
Mean price target
2. Current target
$29.15
Latest analyst target
3. DCF / Fair value
$-8.41
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$29.15
Low
$29.00
High
$41.00
Mean
$35.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-16 main Piper Sandler Overweight → Overweight $40
2026-03-04 main HC Wainwright & Co. Buy → Buy $34
2026-02-10 main Citigroup Buy → Buy $35
2026-02-10 main HC Wainwright & Co. Buy → Buy $33
2026-02-09 main Guggenheim Buy → Buy $30
2025-12-15 main Leerink Partners Outperform → Outperform $32
2025-12-15 main Goldman Sachs Buy → Buy $33
2025-12-12 main HC Wainwright & Co. Buy → Buy $26
2025-11-11 main Citigroup Buy → Buy $26
2025-10-29 main Citigroup Buy → Buy $25
2025-09-18 main Goldman Sachs Buy → Buy $24
2025-09-18 main Jefferies Buy → Buy $20
2025-09-18 main JP Morgan Overweight → Overweight $20
2025-09-18 main Guggenheim Buy → Buy $21
2025-09-18 main Leerink Partners Outperform → Outperform $22
2025-09-18 main B of A Securities Neutral → Neutral $17
2025-09-18 main HC Wainwright & Co. Buy → Buy $20
2025-09-02 init Citigroup — → Buy $16
2025-06-18 reit HC Wainwright & Co. Buy → Buy $18
2025-05-28 reit HC Wainwright & Co. Buy → Buy $18
News
RSS: Latest ROIV news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-20 VENKER ERIC Officer — 200,000 $29.59 $5,918,000
2026-04-20 VENKER ERIC Officer — 200,000 $3.85 $770,000
2026-04-20 HUMES JENNIFER Officer — 29,173 $0.00 $0
2026-04-17 MOMTAZEE JAMES C Director — 469 $0.00 $0
2026-04-17 OREN ILAN Director — 896 $0.00 $0
2026-04-17 EPPERLY MELISSA B Director — 670 $0.00 $0
2026-04-16 GLINE MATTHEW Chief Executive Officer — 289,774 $29.16 $8,449,810
2026-04-08 HUMES JENNIFER Officer — 13,538 $28.37 $384,073
2026-03-30 SUKHATME MAYUKH President — 58,391 — —
2026-03-30 GLINE MATTHEW Chief Executive Officer — 97,319 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Revenue
29.05
-11.19%
32.71
+3.75%
31.53
-42.97%
55.29
Operating Revenue
29.05
-11.19%
32.71
+3.75%
31.53
-42.97%
55.29
Cost Of Revenue
0.91
-43.03%
1.60
-47.30%
3.03
-66.16%
8.97
Reconciled Cost Of Revenue
0.91
-43.03%
1.60
-47.30%
3.03
-66.16%
8.97
Gross Profit
28.14
-9.55%
31.11
+9.19%
28.50
-38.48%
46.32
Operating Expense
1,141.82
+33.38%
856.04
+2.21%
837.51
-33.43%
1,258.07
Research And Development
550.41
+25.12%
439.91
-3.12%
454.06
-6.00%
483.04
Selling General And Administration
591.41
+42.12%
416.13
+8.52%
383.45
-50.52%
775.03
General And Administrative Expense
591.41
+42.12%
416.13
+8.52%
383.45
-50.52%
775.03
Other Gand A
591.41
+42.12%
416.13
+8.52%
383.45
-50.52%
775.03
Total Expenses
1,142.73
+33.24%
857.64
+2.03%
840.54
-33.66%
1,267.03
Operating Income
-1,113.68
-35.00%
-824.93
-1.97%
-809.01
+33.24%
-1,211.75
Total Operating Income As Reported
-1,003.29
-122.31%
4,497.03
+595.94%
-906.76
+32.91%
-1,351.64
EBITDA
-1,099.61
-36.96%
-802.89
-1.61%
-790.16
+13.24%
-910.77
Normalized EBITDA
-1,268.29
+79.24%
-6,109.65
-771.73%
-700.87
+41.54%
-1,198.86
Reconciled Depreciation
14.07
-36.15%
22.04
+16.86%
18.86
+217.89%
5.93
EBIT
-1,113.68
-35.00%
-824.93
-1.97%
-809.01
+11.75%
-916.71
Total Unusual Items
168.68
-96.82%
5,306.76
+6043.42%
-89.29
-130.99%
288.08
Total Unusual Items Excluding Goodwill
168.68
-96.82%
5,306.76
+6043.42%
-89.29
-130.99%
288.08
Special Income Charges
113.50
-97.88%
5,354.73
+7920.21%
-68.47
-0.13%
-68.38
Other Special Charges
—
26.45
-72.94%
97.75
+33.13%
73.42
Restructuring And Mergern Acquisition
—
26.45
-72.94%
97.75
-30.13%
139.89
Net Income
-171.98
-103.95%
4,348.93
+531.00%
-1,009.03
-19.37%
-845.26
Pretax Income
-681.59
-114.92%
4,567.86
+616.15%
-884.99
+4.20%
-923.75
Net Non Operating Interest Income Expense
258.38
+76.46%
146.43
+354.96%
32.18
+582.37%
-6.67
Interest Expense Non Operating
—
34.78
+24.35%
27.97
+297.22%
7.04
Net Interest Income
258.38
+76.46%
146.43
+354.96%
32.18
+582.37%
-6.67
Interest Expense
—
34.78
+24.35%
27.97
+297.22%
7.04
Interest Income Non Operating
258.38
+76.46%
146.43
+354.96%
32.18
+8621.95%
0.37
Interest Income
258.38
+76.46%
146.43
+354.96%
32.18
+8621.95%
0.37
Other Income Expense
173.72
-96.69%
5,246.36
+4950.55%
-108.16
-136.71%
294.67
Other Non Operating Income Expenses
5.04
+108.34%
-60.40
-220.05%
-18.87
-386.33%
6.59
Gain On Sale Of Security
55.19
+215.04%
-47.97
-130.47%
-20.82
-105.84%
356.46
Gain On Sale Of Business
113.50
-97.89%
5,381.18
+18280.86%
29.28
+480.76%
5.04
Tax Provision
48.17
+124.03%
21.50
+426.78%
4.08
+1006.23%
0.37
Tax Rate For Calcs
0.00
+5219.15%
0.00
-97.53%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
42.17
+69.07%
24.94
+247.02%
-16.96
-130.99%
54.74
Net Income Including Noncontrolling Interests
-356.73
-108.43%
4,231.21
+479.32%
-1,115.46
-20.71%
-924.12
Net Income From Continuing Operation Net Minority Interest
-545.01
-111.69%
4,664.07
+695.94%
-782.64
+7.41%
-845.26
Net Income From Continuing And Discontinued Operation
-171.98
-103.95%
4,348.93
+531.00%
-1,009.03
-19.37%
-845.26
Net Income Continuous Operations
-729.76
-116.05%
4,546.35
+611.36%
-889.07
+3.79%
-924.12
Net Income Discontinuous Operations
373.03
+218.37%
-315.15
-39.20%
-226.39
0.00
Minority Interests
184.75
+56.94%
117.72
+10.60%
106.43
+34.97%
78.85
Normalized Income
-671.52
-8.71%
-617.74
+13.03%
-710.32
+34.15%
-1,078.61
Net Income Common Stockholders
-171.98
-103.95%
4,348.93
+531.00%
-1,009.03
-19.37%
-845.26
Diluted EPS
-0.24
-104.59%
5.23
+468.31%
-1.42
-12.70%
-1.26
Basic EPS
-0.24
-104.59%
5.23
+468.31%
-1.42
-12.70%
-1.26
Basic Average Shares
725.40
-7.39%
783.25
+9.88%
712.79
+6.43%
669.75
Diluted Average Shares
725.40
-12.71%
831.05
+16.59%
712.79
+6.43%
669.75
Diluted NI Availto Com Stockholders
-171.98
-103.95%
4,348.93
+531.00%
-1,009.03
-19.37%
-845.26
Earnings From Equity Interest
—
—
—
0.00
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total Assets
5,436.94
-24.72%
7,222.48
+202.25%
2,389.60
-7.56%
2,585.13
Current Assets
5,000.06
-25.73%
6,731.83
+274.28%
1,798.59
-16.21%
2,146.52
Cash Cash Equivalents And Short Term Investments
4,886.89
-24.76%
6,494.95
+287.34%
1,676.81
-18.62%
2,060.40
Cash And Cash Equivalents
2,715.41
-58.19%
6,494.95
+287.34%
1,676.81
-18.62%
2,060.40
Cash Equivalents
2,621.46
-58.47%
6,312.29
—
—
Cash Financial
93.95
-48.56%
182.66
—
—
Other Short Term Investments
2,171.48
0.00
—
—
Receivables
—
82.81
+119.99%
37.64
+459.18%
6.73
Accounts Receivable
—
53.55
+76.26%
30.38
+683.37%
3.88
Taxes Receivable
—
1.83
-22.45%
2.36
-17.45%
2.85
Accrued Interest Receivable
—
27.44
+458.99%
4.91
—
Inventory
—
35.25
+1176.75%
2.76
0.00
Prepaid Assets
—
55.10
-9.42%
60.83
+13.97%
53.37
Restricted Cash
—
5.37
+7.10%
5.01
+28.39%
3.90
Assets Held For Sale Current
0.00
-100.00%
156.27
—
—
Other Current Assets
113.17
+40.40%
80.61
+418.99%
15.53
-29.78%
22.12
Total Non Current Assets
436.88
-10.96%
490.65
-16.98%
591.02
+34.75%
438.61
Net PPE
101.08
+70.38%
59.32
-35.75%
92.34
+6.20%
86.95
Gross PPE
101.08
+70.38%
59.32
-35.75%
92.34
+6.20%
86.95
Other Properties
101.08
+70.38%
59.32
-35.75%
92.34
+6.20%
86.95
Goodwill And Other Intangible Assets
—
137.84
-4.86%
144.88
0.00
Investments And Advances
302.94
+22.27%
247.75
-18.59%
304.32
-6.60%
325.83
Other Investments
302.94
+22.27%
247.75
-18.59%
304.32
-6.60%
325.83
Other Non Current Assets
32.86
-82.10%
183.58
+271.00%
49.48
+91.62%
25.82
Total Liabilities Net Minority Interest
249.74
-67.73%
773.95
-1.03%
782.02
+49.33%
523.70
Current Liabilities
149.41
-43.99%
266.76
-2.09%
272.45
+47.77%
184.37
Payables And Accrued Expenses
84.47
-9.49%
93.33
-29.69%
132.75
+11.97%
118.56
Payables
24.11
+1.28%
23.80
-37.97%
38.37
+8.73%
35.29
Accounts Payable
23.69
+68.87%
14.03
-62.92%
37.83
+9.39%
34.58
Current Accrued Expenses
60.37
-13.18%
69.53
-26.33%
94.37
+13.34%
83.27
Pensionand Other Post Retirement Benefit Plans Current
53.93
+8.09%
49.89
-9.60%
55.19
+24.68%
44.26
Total Tax Payable
0.42
-95.74%
9.77
+1703.14%
0.54
-23.45%
0.71
Income Tax Payable
0.42
-95.74%
9.77
+1703.14%
0.54
-23.45%
0.71
Current Debt And Capital Lease Obligation
9.84
+9.77%
8.97
-82.89%
52.41
+359.84%
11.40
Current Debt
—
12.00
-70.53%
40.72
—
Other Current Borrowings
—
12.00
-70.53%
40.72
—
Current Capital Lease Obligation
9.84
+9.77%
8.97
-23.32%
11.69
+2.59%
11.40
Current Deferred Liabilities
1.17
-71.98%
4.17
-66.51%
12.44
+22.64%
10.15
Current Deferred Revenue
1.17
-71.98%
4.17
-66.51%
12.44
+22.64%
10.15
Other Current Liabilities
—
110.41
+5182.54%
2.09
-80.75%
10.86
Total Non Current Liabilities Net Minority Interest
100.33
-80.22%
507.19
-0.47%
509.57
+50.17%
339.33
Liabilities Heldfor Sale Non Current
0.00
-100.00%
433.94
—
—
Long Term Debt And Capital Lease Obligation
90.33
+100.64%
45.02
-89.51%
428.99
+57.43%
272.49
Long Term Debt
—
430.59
+14.67%
375.51
+78.80%
210.03
Long Term Capital Lease Obligation
90.33
+100.64%
45.02
-15.81%
53.48
-14.39%
62.47
Non Current Deferred Liabilities
—
—
—
13.74
Non Current Deferred Revenue
—
—
—
13.74
Other Non Current Liabilities
10.00
-64.57%
28.23
-64.97%
80.58
+20.56%
66.83
Stockholders Equity
4,687.60
-21.46%
5,968.58
+415.53%
1,157.77
-30.13%
1,656.94
Common Stock Equity
4,687.60
-21.46%
5,968.58
+415.53%
1,157.77
-30.13%
1,656.94
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
695.94
-13.73%
806.68
+6.12%
760.14
+9.38%
694.98
Ordinary Shares Number
695.94
-13.73%
806.68
+6.12%
760.14
+9.38%
694.98
Additional Paid In Capital
4,562.11
-15.46%
5,396.49
+9.39%
4,933.14
+11.57%
4,421.61
Retained Earnings
116.06
-79.86%
576.17
+115.27%
-3,772.75
-36.51%
-2,763.72
Gains Losses Not Affecting Retained Earnings
9.44
+331.15%
-4.08
-56.02%
-2.62
-176.64%
-0.95
Minority Interest
499.59
+4.09%
479.95
+6.70%
449.82
+11.21%
404.49
Other Equity Adjustments
9.44
+331.15%
-4.08
-56.02%
-2.62
-176.64%
-0.95
Total Equity Gross Minority Interest
5,187.20
-19.56%
6,448.53
+301.13%
1,607.59
-22.02%
2,061.43
Total Capitalization
4,687.60
-21.46%
5,968.58
+289.27%
1,533.28
-17.87%
1,866.97
Working Capital
4,850.65
-24.97%
6,465.07
+323.62%
1,526.14
-22.22%
1,962.16
Invested Capital
4,687.60
-21.46%
5,968.58
+279.20%
1,574.00
-15.69%
1,866.97
Total Debt
100.17
+85.55%
53.99
-88.79%
481.40
+69.57%
283.89
Capital Lease Obligations
100.17
+85.55%
53.99
-17.16%
65.17
-11.77%
73.87
Net Tangible Assets
4,687.60
-21.46%
5,968.58
+489.27%
1,012.88
-38.87%
1,656.94
Tangible Book Value
4,687.60
-21.46%
5,968.58
+489.27%
1,012.88
-38.87%
1,656.94
Current Provisions
—
23.28
+32.49%
17.57
—
Line Item Trend 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Operating Cash Flow
-839.45
-9.69%
-765.27
+9.26%
-843.39
-24.44%
-677.73
Cash Flow From Continuing Operating Activities
-839.45
-9.69%
-765.27
+9.26%
-843.39
-24.44%
-677.73
Net Income From Continuing Operations
-356.73
-108.43%
4,231.21
+479.32%
-1,115.46
-20.71%
-924.12
Depreciation Amortization Depletion
14.07
-36.15%
22.04
+16.86%
18.86
+217.89%
5.93
Depreciation And Amortization
14.07
-36.15%
22.04
+16.86%
18.86
+217.89%
5.93
Other Non Cash Items
-102.47
-206.70%
96.04
+155.77%
37.55
-54.63%
82.76
Stock Based Compensation
289.03
+44.78%
199.63
-8.34%
217.78
-61.45%
564.96
Operating Gains Losses
-481.15
+91.06%
-5,381.18
-18280.86%
-29.28
+94.26%
-510.27
Gain Loss On Investment Securities
—
—
—
-505.23
Unrealized Gain Loss On Investment Securities
-55.19
-215.04%
47.97
+130.47%
20.82
-76.15%
87.29
Change In Working Capital
-77.05
-504.76%
19.04
+200.00%
6.34
-59.63%
15.72
Change In Payables And Accrued Expense
-28.24
-133.30%
84.81
+37.04%
61.89
-6.23%
66.00
Change In Accrued Expense
-10.07
-116.21%
62.13
+8.00%
57.53
+13.70%
50.59
Change In Payable
-18.17
-180.09%
22.68
+420.39%
4.36
-71.70%
15.40
Change In Account Payable
-18.17
-180.09%
22.68
+420.39%
4.36
-71.70%
15.40
Change In Other Working Capital
—
—
3.30
+121.43%
-15.41
Change In Other Current Assets
-33.83
+47.95%
-64.99
-32.40%
-49.09
-75.31%
-28.00
Change In Other Current Liabilities
-14.98
-1805.85%
-0.79
+87.82%
-6.46
+5.97%
-6.87
Investing Cash Flow
-1,766.29
-133.94%
5,203.62
+11854.55%
-44.27
-114.60%
303.30
Cash Flow From Continuing Investing Activities
-1,766.29
-133.94%
5,203.62
+11854.55%
-44.27
-114.60%
303.30
Net PPE Purchase And Sale
-4.60
-232.78%
-1.38
+89.11%
-12.69
+27.22%
-17.44
Purchase Of PPE
-4.60
-232.78%
-1.38
+89.11%
-12.69
+27.22%
-17.44
Capital Expenditure
-4.60
-232.78%
-1.38
+89.11%
-12.69
+27.22%
-17.44
Net Investment Purchase And Sale
-2,101.52
0.00
0.00
-100.00%
320.17
Purchase Of Investment
-4,061.52
0.00
0.00
—
Sale Of Investment
1,960.00
0.00
0.00
-100.00%
320.17
Net Business Purchase And Sale
229.36
+720.18%
-36.98
-134.29%
107.86
+276651.28%
-0.04
Purchase Of Business
-31.22
+63.04%
-84.48
-1159.81%
-6.71
-17094.87%
-0.04
Gain Loss On Sale Of Business
-379.61
-1058.35%
-32.77
-11.94%
-29.28
-480.76%
-5.04
Net Other Investing Changes
110.47
-97.89%
5,241.99
+3859.48%
-139.43
-23339.00%
0.60
Financing Cash Flow
-1,219.79
-390.87%
419.36
-16.04%
499.46
+62.80%
306.79
Cash Flow From Continuing Financing Activities
-1,219.79
-390.87%
419.36
-16.04%
499.46
+62.80%
306.79
Net Issuance Payments Of Debt
-52.75
-71.81%
-30.70
-123.66%
129.75
+776.13%
14.81
Issuance Of Debt
0.00
0.00
-100.00%
159.90
+339.28%
36.40
Repayment Of Debt
-52.75
-71.81%
-30.70
-1.86%
-30.14
-39.62%
-21.59
Long Term Debt Issuance
0.00
0.00
-100.00%
159.90
+339.28%
36.40
Long Term Debt Payments
-52.75
-71.81%
-30.70
-1.86%
-30.14
-39.62%
-21.59
Net Long Term Debt Issuance
-52.75
-71.81%
-30.70
-123.66%
129.75
+776.13%
14.81
Net Common Stock Issuance
-1,180.45
-369.17%
438.56
+15.50%
379.71
0.00
Common Stock Payments
-1,293.23
0.00
0.00
—
Repurchase Of Capital Stock
-1,293.23
0.00
0.00
—
Proceeds From Stock Option Exercised
50.62
-8.34%
55.23
+1664.50%
3.13
-96.88%
100.41
Net Other Financing Charges
-37.22
+14.87%
-43.72
-232.91%
-13.13
-106.85%
191.57
Changes In Cash
-3,825.54
-178.75%
4,857.72
+1351.34%
-388.20
-473.90%
-67.64
Effect Of Exchange Rate Changes
0.75
+21.27%
0.62
-90.19%
6.28
0.00
Beginning Cash Position
6,550.45
+287.12%
1,692.12
-18.41%
2,074.03
-3.16%
2,141.68
End Cash Position
2,725.66
-58.39%
6,550.45
+287.12%
1,692.12
-18.41%
2,074.03
Free Cash Flow
-844.05
-10.10%
-766.65
+10.45%
-856.08
-23.15%
-695.16
Interest Paid Supplemental Data
5.96
-41.93%
10.27
+93.63%
5.30
-4.19%
5.54
Income Tax Paid Supplemental Data
61.91
+401.13%
12.35
+140.91%
5.13
+459.83%
0.92
Amortization Of Securities
-69.96
0.00
0.00
—
Change In Interest Payable
0.00
-100.00%
21.98
+18.34%
18.57
—
Common Stock Issuance
112.78
-74.28%
438.56
+15.50%
379.71
0.00
Earnings Losses From Equity Investments
—
—
—
0.00
Issuance Of Capital Stock
112.78
-74.28%
438.56
+15.50%
379.71
0.00
Sale Of Business
260.59
+448.60%
47.50
-58.54%
114.56
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category